Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 25 - 99 |
| Updated: | 10/19/2018 |
| Start Date: | July 23, 2018 |
| End Date: | June 2021 |
| Contact: | Terlika Sood |
| Email: | Terlika.Sood@nyulangone.org |
| Phone: | 212 263 2717 |
The role of fat in breast cancer development and growth has been studied extensively using
body mass index, a measure of whole body fatness, and dietary fat intake in a number of
epidemiological studies. However, there is a paucity of studies, on an individual level, to
assess the role of breast fat itself in breast cancer due to lack of a non-invasive and fast
measurement method. Since breast fibroglandular cells are surrounded by breast fat cells, the
characteristics of breast fat may have a stronger relationship with breast cancer
development, as supported by recent studies showing that a majority of breast cancer develops
at the interface between fibroglandular tissue and adipose tissue. However, it is not trivial
to study the role of breast fat, mainly due to the lack of a non-invasive and fast
measurement method sensitive enough to important features of breast fat, such as types of
fat.Recently, we have developed a rapid MRI method, referred to as Gradient-echo
Spectroscopic Imaging (GSI), to measure fatty acid composition during clinical breast MRI
exams. GSI can provide map of saturated fat and unsaturated fats in the breast adipose tissue
without performing tissue biopsy. Our pilot study found that the postmenopausal women with
aggressive breast cancer, known as invasive ductal carcinoma, have a significantly higher
percentage of saturated fat in their breast adipose tissue than the postmenopausal women with
only benign lesions.
body mass index, a measure of whole body fatness, and dietary fat intake in a number of
epidemiological studies. However, there is a paucity of studies, on an individual level, to
assess the role of breast fat itself in breast cancer due to lack of a non-invasive and fast
measurement method. Since breast fibroglandular cells are surrounded by breast fat cells, the
characteristics of breast fat may have a stronger relationship with breast cancer
development, as supported by recent studies showing that a majority of breast cancer develops
at the interface between fibroglandular tissue and adipose tissue. However, it is not trivial
to study the role of breast fat, mainly due to the lack of a non-invasive and fast
measurement method sensitive enough to important features of breast fat, such as types of
fat.Recently, we have developed a rapid MRI method, referred to as Gradient-echo
Spectroscopic Imaging (GSI), to measure fatty acid composition during clinical breast MRI
exams. GSI can provide map of saturated fat and unsaturated fats in the breast adipose tissue
without performing tissue biopsy. Our pilot study found that the postmenopausal women with
aggressive breast cancer, known as invasive ductal carcinoma, have a significantly higher
percentage of saturated fat in their breast adipose tissue than the postmenopausal women with
only benign lesions.
The overarching goal of this study is to determine the role of saturated fatty acid in breast
cancer development and growth. In this proposal, GSI will be used for non-invasive in vivo
measurement of saturated fat in the breast adipose tissue of postmenopausal women who undergo
diagnostic breast MRI exams (Aims 1 and 2) or MRI-guided biopsy scans (Aim 3). The central
hypotheses is that (i) the breast saturated fatty acid fraction measured by GSI is associated
with the presence of malignant lesions in the breast and (ii) the breast saturated fatty acid
fraction correlates positively with inflammation in the breast adipose tissue that may lead
to increase in estrogen production in adipocytes.The proposed study will evaluate whether
breast saturated fat is an independent risk factor for breast cancer, and whether it can
provide additional diagnostic information to current clinical diagnostic exams. In addition,
the proposed imaging measure of breast saturated fat can be used to assess the efficacy of
any intervention to reduce cancer-related inflammation in the breast adipose tissue and to
investigate the possible role of fatty acid composition in prevention and clinical management
of breast cancer.
cancer development and growth. In this proposal, GSI will be used for non-invasive in vivo
measurement of saturated fat in the breast adipose tissue of postmenopausal women who undergo
diagnostic breast MRI exams (Aims 1 and 2) or MRI-guided biopsy scans (Aim 3). The central
hypotheses is that (i) the breast saturated fatty acid fraction measured by GSI is associated
with the presence of malignant lesions in the breast and (ii) the breast saturated fatty acid
fraction correlates positively with inflammation in the breast adipose tissue that may lead
to increase in estrogen production in adipocytes.The proposed study will evaluate whether
breast saturated fat is an independent risk factor for breast cancer, and whether it can
provide additional diagnostic information to current clinical diagnostic exams. In addition,
the proposed imaging measure of breast saturated fat can be used to assess the efficacy of
any intervention to reduce cancer-related inflammation in the breast adipose tissue and to
investigate the possible role of fatty acid composition in prevention and clinical management
of breast cancer.
Inclusion Criteria:
- No contraindications to MRI scanning (pacemaker, implanted metallic objects, severe
obesity or other condition that leads to difficulty lying in the magnet)
- No contraindication to gadolinium contrast agent (severe renal insufficiency
(EGFR<30), allergy to gadolinium) which will be injected for clinical exam
- Able and willing to provide informed consent
- Post-menopausal age > 25 years.
Exclusion Criteria:
- Contra-indication to MRI or gadolinium contrast agent (have a pacemaker, aneurysm
clip, or other metallic implant; weigh >135 kg; or have renal impairment)
- Breast surgery within prior 12 months, or breast implants
- Any hormonal therapy
We found this trial at
1
site
Click here to add this to my saved trials
